Literature DB >> 23590851

Initial treatment failure in patients with complicated skin and skin structure infections.

Ariel Berger1, Gerry Oster, John Edelsberg, Xingyue Huang, David J Weber.   

Abstract

BACKGROUND: Consequences of initial antibiotic failure in patients hospitalized for complicated skin and skin-structure infections (cSSSI) are not well understood.
METHODS: Using data from >100 hospitals in the United States, we identified all adults hospitalized for cSSSI between January 1, 2000 and June 30, 2009. We defined "initial therapy" as all parenteral antibiotics administered <24 h of admission, and such therapy was assumed to have failed if the patient (1) received new antibiotic(s) subsequently (excluding similar/narrower spectrum antibiotics or those begun at discharge), or (2) underwent drainage/debridement/amputation>72 h after admission. We limited attention to the 40 most commonly used antibiotic regimens in 2009. We compared clinical and economic outcomes of patients who experienced initial treatment failure and those who did not.
RESULTS: The rate of initial treatment failure was 16.6% in acute infections (n=13,498), 34.1% in chronic/ulcerative infections (n=1,116), and 26.7% in surgical site infections (SSIs) (n=2,929). Treatment failure was associated with 4.1-7.3 additional days in the hospital and $11,995-$23,655 in additional inpatient charges; the case fatality rate was from 4- to 12-fold higher in patients who experienced treatment failure than in those who did not (all comparisons, p<0.01).
CONCLUSION: Initial treatment failure in patients hospitalized for cSSSI is associated with significantly worse clinical outcomes, longer hospital stays, and higher hospital charges than with successful initial treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590851     DOI: 10.1089/sur.2012.103

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  12 in total

Review 1.  Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure.

Authors:  Abraham Pulido-Cejudo; Mario Guzmán-Gutierrez; Abel Jalife-Montaño; Alejandro Ortiz-Covarrubias; Jose Luis Martínez-Ordaz; Héctor Faustino Noyola-Villalobos; Luis Mauricio Hurtado-López
Journal:  Ther Adv Infect Dis       Date:  2017-08-31

2.  Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

Authors:  T D Trinh; S C J Jorgensen; E J Zasowski; K C Claeys; A M Lagnf; S J Estrada; D J Delaportes; V Huang; K P Klinker; K S Kaye; S L Davis; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.

Authors:  Andrew F Shorr; Thomas P Lodise; G Ralph Corey; Carisa De Anda; Edward Fang; Anita F Das; Philippe Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

4.  Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study.

Authors:  Javier Garau; Francesco Blasi; Jesús Medina; Kyle McBride; Helmut Ostermann
Journal:  BMC Infect Dis       Date:  2015-02-19       Impact factor: 3.090

Review 5.  World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections.

Authors:  Massimo Sartelli; Mark A Malangoni; Addison K May; Pierluigi Viale; Lillian S Kao; Fausto Catena; Luca Ansaloni; Ernest E Moore; Fred A Moore; Andrew B Peitzman; Raul Coimbra; Ari Leppaniemi; Yoram Kluger; Walter Biffl; Kaoru Koike; Massimo Girardis; Carlos A Ordonez; Mario Tavola; Miguel Cainzos; Salomone Di Saverio; Gustavo P Fraga; Igor Gerych; Michael D Kelly; Korhan Taviloglu; Imtiaz Wani; Sanjay Marwah; Miklosh Bala; Wagih Ghnnam; Nissar Shaikh; Osvaldo Chiara; Mario Paulo Faro; Gerson Alves Pereira; Carlos Augusto Gomes; Federico Coccolini; Cristian Tranà; Davide Corbella; Pietro Brambillasca; Yunfeng Cui; Helmut A Segovia Lohse; Vladimir Khokha; Kenneth Yy Kok; Suk-Kyung Hong; Kuo-Ching Yuan
Journal:  World J Emerg Surg       Date:  2014-11-18       Impact factor: 5.469

6.  A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.

Authors:  William O'Riordan; Alison McManus; Juri Teras; Ivan Poromanski; Maria Cruz-Saldariagga; Megan Quintas; Laura Lawrence; ShuJui Liang; Sue Cammarata
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

Review 7.  Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.

Authors:  Keith S Kaye; Lindsay A Petty; Andrew F Shorr; Marya D Zilberberg
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 8.  Current Treatment Options for Acute Skin and Skin-structure Infections.

Authors:  Yoav Golan
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

9.  Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center.

Authors:  Kimberly C Claeys; Abdalhamid M Lagnf; Trishna B Patel; Manu G Jacob; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2015-06-09

10.  Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.

Authors:  J Pullman; J Gardovskis; B Farley; E Sun; M Quintas; L Lawrence; R Ling; S Cammarata
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.